Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases
Shots:
- Formycon along with its partners Polpharma Biologics Group BV, Bioeq AG & Teva Canada have received Health Canada’s Notice of Compliance (NOC) for Ranopto (FYB201, biosimilar Lucentis) for the treatment of various retinal diseases in Canada
- Ranopto was developed by Bioeq (JV of Formycon & Polpharma Biologics). In mid-2021, Teva entered a strategic partnership for the exclusive commercialization of FYB201 in Canada, Europe & other selected countries
- Teva expects to launch Ranopto in the Canada market by Q1’24. Ranibizumab functions by inhibiting the VEGF responsible for the excessive formation of blood vessels in the retina
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
